This study is looking at the detection of vasoactive peptides in portal hypertension.
..Date First Received: September 13, 2005
Last Updated: July 25, 2007
Verified by: Bayside Health, September 2005
Clinical Trial Phase: N/A | Start Date:
Overall Status: Recruiting
Brief Summary
Condition Keyword(s):
Intervention(s):
This study is looking at the detection of vasoactive peptides in portal hypertension.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: Norfloxacin
Criteria for Participation in this Clinical Trial
- Inclusion Criteria: - HVPG >= 12 mmHg
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 75 Years
Clinical Trial Sponsor Information
Lead Sponsor: Bayside Health
Overall Clinical Trial Officials and Contacts
William W Kemp, MBBS, FRACP Principal Investigator The Alfred
Overall Contact: William W Kemp, MBBS, FRACP 92762000 w.kemp@alfred.org.au
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00163982
Study ID Number: AH4204
ClinicalTrials.gov Identifier: NCT00163982
Health Authority: Australia: Human Research Ethics Committee
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
